$HURA News

TuHURA Biosciences Q1 EPS $(0.13) Misses $(0.12) Estimate

Citizens Initiates Coverage On TuHURA Biosciences with Market Outperform Rating, Announces Price Target of $9

TuHURA Biosciences Enters Loan Agreement For Credit Facility Of Up To $50M For Its Pipeline, Ongoing Clinical Trials And General Corporate Expenses

Watching TuHURA Biosciences; Zacks Small-Cap Research Gives Stock $7 Price Valuation

Watching TuHURA Biosciences; Zacks Small-Cap Research Gives Stock $7 Price Valuation

TuHURA Biosciences Files $50M At-The-Market Common Stock Offering With H.C. Wainwright As Sales Agent

TuHURA Biosciences Q4 EPS $(0.13) Beats $(0.14) Estimate

TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

TuHURA Biosciences Regains Nasdaq Compliance

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences

TuHURA Biosciences shares are trading lower. The company announced it filed an IND with the FDA Division of Hematologic Malignancies 1 for the study of TBS-2025 in blood-related cancer treatment.

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers

TuHURA Biosciences Files IND With FDA DHM1 For Study Of TBS-2025, VISTA Inhibiting Antibody, For Treatment Of mutNPM1 r/r AML In Combination With Menin Inhibitor

TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

HC Wainwright & Co. Reiterates Buy on TuHURA Biosciences, Maintains $10 Price Target

TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

TuHURA Biosciences Granted Orphan Drug Designation From FDA For Its Treatment Of Stage IIB To Stage IV Cutaneous Melanoma

HURA: Focus on the Delta Opioid Receptor

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

TuHURA Biosciences Announces Kintara's REM-001 Trial Meets Primary Endpoint In Metastatic Cutaneous Breast Cancer